Rayner is a leading developer and manufacturer of ophthalmic implants and pharmaceuticals.
We specialise in intraocular lenses (IOLs) and related products used in cataract and refractive surgery. Since the manufacture of the world’s first IOL by Rayner in 1949, we have continuously pioneered IOL design with the goal of improving vision and restoring sight worldwide. Today, over 28 million IOLs are implanted around the world every year, and it is globally the most performed elective surgical procedure.
Our mission is to deliver innovative and clinically superior ophthalmic solutions that respond to the expectations of our global customers to improve sight and quality of life for their patients.
In June 2021 we were extremely pleased to announce that CVC Capital Partners will support the continuing internationalisation of Rayner by acquiring a majority interest in our Company.
With CVC’s backing and working in partnership with our ambitious management team, we will pursue a strategy focused on driving both organic and inorganic growth, while further enhancing Rayner’s established reputation for innovation and product excellence. Benefitting from CVC’s international reach and experience of the healthcare sector, Rayner is poised to continue its growth as a leading global operator as demand for its broad suite of products and services in ophthalmology continues to grow.
Tim Clover, CEO of Rayner, remarked on the announcement: “Having recently tripled our manufacturing capacity and strengthened our R&D capability, we are primed to embark on our next phase of growth and improve outcomes for even more patients with our world-class implants and treatments for a broad range of ophthalmic conditions.
With its extensive healthcare experience, CVC understands our business and supports our ambition to become an international ophthalmology leader.”
We are headquartered in Worthing, UK and have a state-of-the-art facility that makes nearly one million IOLs a year, which are sold in over 80 countries worldwide. Rayner now employs over 500 people worldwide in roles that are varied and diverse – such as skilled technicians, materials scientists, regulatory specialists, Sales and Marketing, Finance, Human Resources, with multilingual customer service teams. Everyone at Rayner is driven to make the very best ophthalmic products, with significant investment in engineering and research & development.
We were thrilled to have this recognised in 2020 when we were awarded the Queen’s Award for Innovation for our innovative RayOne fully preloaded injector system.